According to Zacks, “Nephros develops advanced End Stage Renal Disease, or ESRD, therapy technology and products that would address both patient treatment needs and the clinical and financial needs of the treatment provider. “
Separately, Taglich Brothers reiterated a “speculative buy” rating on shares of Nephros in a report on Wednesday, April 24th.
Nephros (OTCMKTS:NEPH) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Nephros had a negative net margin of 52.25% and a negative return on equity of 56.46%. The business had revenue of $1.77 million for the quarter, compared to analysts’ expectations of $1.70 million. Equities analysts expect that Nephros will post -0.07 earnings per share for the current year.
In other news, insider Daron Evans bought 43,172 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was bought at an average cost of $0.60 per share, for a total transaction of $25,903.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.80% of the company’s stock.
Nephros, Inc, a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. It operates through two segments, Water Filtration and Renal Products. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities.
See Also: How accurate is the Rule of 72?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nephros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nephros and related companies with MarketBeat.com's FREE daily email newsletter.